Pharmacogenomics of Human Drug Transporters

Sets the foundation for safer, more effective drug therapies

With this book as their guide, readers will discover how to apply our current understanding of the pharmacogenomics of drug transporters to advance their own drug discovery and development efforts. In particular, the book explains how new findings in the field now enable researchers to more accurately predict drug interactions and adverse drug reactions. Moreover, it sets the foundation for the development of drug therapies that are tailored to an individual patient’s genetics. Pharmacogenomics of Human Drug Transporters serves as a comprehensive guide to how transporters regulate the absorption, distribution, and elimination of drugs in the body as well as how an individual’s genome affects those processes. The book’s eighteen chapters have been authored by a team of leading pioneers in the field. Based on their own laboratory and clinical experience as well as a thorough review of the literature, these authors explore all facets of drug transporter pharmacogenomics, including:

Individual drug transporters and transporter families and their clinical significance
Principles of altered drug transport in drug–drug interactions, pharmacotherapy, and personalized medicine
Emerging new technologies for rapid detection of genetic polymorphisms
Clinical aspects of genetic polymorphisms in major drug transporter genes
Future research directions of drug transporter pharmacogenomics and the prospect of individualized medicine

Pharmacogenomics of Human Drug Transporters opens the door to new drug discovery and development breakthroughs leading to safer and more effective customized drug therapies.The book is recommended for pharmaceutical scientists, biochemists, pharmacologists, clinicians, and genetics and genomics researchers.

Author Biography

TOSHIHISA ISHIKAWA, PhD, is Senior Scientist at RIKENYokohama Institute and Professor of Biochemistry, MolecularBiology, and Pharmacogenomics at Yokohama City University’sGraduate School of Medicine. Previously, Dr. Ishikawa was theDirector of the Department of Research Technology Development atPfizer, Japan. A recipient of the Achievement Award from theInternational Life Sciences Institute (ILSI), Dr. Ishikawa is alsothe cofounder of the International Transporter Consortium(ITC). RICHARD B. KIM, MD, FRCPC, is Professor and Chair of theDivision of Clinical Pharmacology and Associate Chair for Researchin the Department of Medicine at the University of Western Ontario.He is a Fellow of the American Association of PharmaceuticalScientists and an elected member of the American Society forClinical Investigation. JORG KONIG, PhD, is Professor and Headof the Molecular Biology Laboratories in the Department of ClinicalPharmacology at the Friedrich-Alexander UniversitatErlangen-Nurnberg.